Wells Fargo & Company Lowers Autolus Therapeutics (NASDAQ:AUTL) Price Target to $6.00

Autolus Therapeutics (NASDAQ:AUTL) had its target price reduced by Wells Fargo & Company from $8.00 to $6.00 in a research report released on Friday,Benzinga reports. They currently have an overweight rating on the stock.

Separately, Needham & Company LLC restated a “buy” rating and set a $10.00 price objective on shares of Autolus Therapeutics in a research note on Monday, January 13th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $9.52.

Autolus Therapeutics Price Performance

Autolus Therapeutics stock opened at $1.70 on Friday. The company has a market cap of $452.36 million, a PE ratio of -1.40 and a beta of 2.07. The company has a fifty day moving average price of $2.02 and a two-hundred day moving average price of $2.90. Autolus Therapeutics has a 12 month low of $1.56 and a 12 month high of $6.60.

Autolus Therapeutics (NASDAQ:AUTL) last posted its earnings results on Thursday, March 20th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.12. The company had revenue of $0.03 million during the quarter, compared to the consensus estimate of $2.98 million. Equities research analysts anticipate that Autolus Therapeutics will post -0.94 earnings per share for the current year.

Institutional Investors Weigh In On Autolus Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of AUTL. FMR LLC raised its stake in shares of Autolus Therapeutics by 44.6% during the third quarter. FMR LLC now owns 17,773,873 shares of the company’s stock valued at $64,519,000 after purchasing an additional 5,478,706 shares in the last quarter. Capstone Investment Advisors LLC bought a new stake in Autolus Therapeutics in the third quarter worth about $51,000. Bellevue Group AG raised its position in Autolus Therapeutics by 27.7% in the third quarter. Bellevue Group AG now owns 41,500 shares of the company’s stock worth $151,000 after acquiring an additional 9,000 shares in the last quarter. Erste Asset Management GmbH bought a new stake in Autolus Therapeutics in the third quarter worth about $708,000. Finally, HighVista Strategies LLC raised its position in Autolus Therapeutics by 2.7% in the third quarter. HighVista Strategies LLC now owns 533,024 shares of the company’s stock worth $1,935,000 after acquiring an additional 14,204 shares in the last quarter. 72.83% of the stock is currently owned by institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.